Question 1

What is essential thrombocythemia (ET)?

Accepted Answer

Essential thrombocythemia (ET) is a rare chronic blood disorder (a myeloproliferative neoplasm) in which the bone marrow produces too many platelets. Abnormal platelet levels can lead to clotting or bleeding complications.
MedlinePlus (NIH), 2023

Question 2

Are thrombocytosis and thrombocythemia the same?

Accepted Answer

Thrombocytosis refers to an elevated platelet count caused by any condition (e.g., infection). Thrombocythemia typically refers to a chronic disorder like ET, where platelet overproduction stems from a bone marrow pathology.
Brière JB, “Essential thrombocythemia,” PMC/NCBI, 2007

Question 3

What are the symptoms of essential thrombocythemia?

Accepted Answer

Many people with ET have no symptoms at first. When symptoms occur, they may include headaches, dizziness, chest pain, tingling in the hands and feet, vision changes, or frequent nosebleeds. Some individuals experience blood clots or unusual bleeding episodes.

Question 4

Can essential thrombocythemia be life-threatening?

Accepted Answer

While often indolent, ET can lead to serious complications like stroke, heart attack, bleeding, or progression to myelofibrosis or acute leukemia. Proper treatment and monitoring greatly reduce these risks.
Tefferi A, “Essential thrombocythemia: A Review,” Am J Hematol, 2024

Question 5

What causes essential thrombocythemia in adults?

Accepted Answer

ET is often caused by acquired mutations in genes such as JAK2, CALR, or MPL. These mutations affect how bone marrow regulates platelet production. ET is not typically inherited, and most cases are considered sporadic, developing later in life.

Question 6

What is thrombocythemia with CALR mutation?

Accepted Answer

CALR-positive essential thrombocythemia refers to a subtype of ET where the CALR (calreticulin) gene mutation is present. This mutation affects cell signaling in the bone marrow and is associated with a lower risk of blood clots compared to JAK2-positive ET. Genetic testing helps classify the mutation type and guide prognosis.

Question 7

How is essential thrombocythemia diagnosed?

Accepted Answer

ET diagnosis involves a high platelet count (typically ?450 × 10?/L), a bone marrow biopsy showing megakaryocyte proliferation, and genetic testing for JAK2, CALR, or MPL mutations, while ruling out other conditions.
Tefferi A, “2024 update on diagnosis,” Am J Hematol, 2024

Question 8

How is essential thrombocythemia treated?

Accepted Answer

Treatment depends on the patient’s age, platelet count, symptoms, and risk of clotting. Common approaches include low-dose aspirin, hydroxyurea, interferon alfa, or JAK inhibitors. Patients are also monitored regularly for changes in disease progression or complications.

Question 9

Can essential thrombocythemia turn into cancer or other conditions?

Accepted Answer

ET is already classified as a type of blood cancer (myeloproliferative neoplasm), although it may remain stable for years. In some cases, it can progress to myelofibrosis or acute myeloid leukemia. Regular follow-up with a hematologist is important for long-term care.

Question 10

Who is most likely to develop essential thrombocythemia?

Accepted Answer

ET most commonly affects adults over age 50, although it can also occur in younger individuals. It is slightly more common in women. Risk factors are not well understood, and most cases occur without a family history or known environmental exposure.

Thrombocythemia Medications